Enzymatic rationale and preclinical support for a potent protein kinase Cβ inhibitor in cancer therapy

Advances in Enzyme Regulation

Volumn 39, Issue 1, 1999, Pages 313-327

  Teicher, Beverly A ^a   Alvarez, Enrique ^a   Mendelsohn, Laurane G ^a   Ara, Gulshan ^b   Menon, Krishna ^a   Ways, D Kirk ^a  

^a ELI LILLY AND COMPANY   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

9 [(DIMETHYLAMINO)METHYL] 6,7,10,11 TETRAHYDRO 9H,18H 5,21:12,17 DIMETHENODIBENZO[E,K]PYRROLO[3,4 H][1,4,13]OXADIAZACYCLOHEXADECINE 18,20(19H) DIONE; ANTINEOPLASTIC AGENT; BISINDOLYLMALEIMIDE; CARBOPLATIN; CARMUSTINE; ENZYME INHIBITOR; GEMCITABINE; INDOLE DERIVATIVE; ISOENZYME; MALEIMIDE DERIVATIVE; PROTEIN KINASE C; PROTEIN KINASE C BETA1; PROTEIN KINASE C INHIBITOR; TAXOL;

ANIMAL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; BRAIN TUMOR; CANCER RADIOTHERAPY; CANCER TRANSPLANTATION; CONFERENCE PAPER; CONTROLLED STUDY; CYTOTOXICITY TEST; DRUG COMBINATION; DRUG EFFECT; DRUG SCREENING; ENZYMOLOGY; EXPERIMENTAL NEOPLASM; FEMALE; GLIOBLASTOMA; HUMAN; HUMAN CELL; LEWIS CARCINOMA; LUNG NON SMALL CELL CANCER; LUNG TUMOR; MALE; METASTASIS; MOUSE; MOUSE STRAIN; MULTIMODALITY CANCER THERAPY; NONHUMAN; NUDE MOUSE; XENOGRAFT;

ANIMALIA; MUS MUSCULUS;

EID: 0032867587     PISSN: 00652571     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0065-2571(98)00026-0     Document Type: Conference Paper

References (66)

1. J. PLUDA, Tumor-associated angiogenesis: mechanisms, clinical implications, and therapeutic strategies, Seminars in Oncology 24, 203-218 (1997).
2. K. NORRBY, Angiogenesis: new aspects relating to its initiation and control, Apmis 105, 417-437 (1997).
3. S. B. FOX and A. L. HARRIS, Markers of tumor angiogenesis: clinical applications in prognosis and anti-angiogenic therapy, Investigational New Drugs 15, 15-28 (1997).
4. W. RISAU, What, if anything, is an angiogenic factor?, Cancer and Metastasis Reviews 15, 149-151 (1996).
5. R. K. SINGH and I. J. FIDLER, Regulation of tumor angiogenesis by organ-specific cytokines, Current Topics in Microbiology and Immunology 213, 1-11 (1996).
6. M. L. IRUELA-ARISPE and H. F. DVORAK, Angiogenesis: a dynamic balance of stimulators and inhibitors, Thrombosis and Haemostasis 78, 672-677 (1997).
7. M. NGUYEN, Angiogenic factors as tumor markers, Investigational New Drugs 15, 29-37 (1997).
8. M. TOI, T. TANIGUCHI, Y. YAMAMOTO, T. KURISAKI, H. SUZUKI and T. TOMINAGA, Clinical significance of the determination of angiogenic factors, European Journal of Cancer 32A, 2513-2519 (1996).
9. Y. TAKEBAYASHI, S. AKIYAMA, S. AKIBA, K. YAMADA, K. MIYADERA, T. SUMIZAWA, Y. YAMADA, F. MURATA and T. AIKOU, Clinicopathologic and prognostic significance of an angiogenic factor, thymidine phosphorylase, in human colorectal carcinoma, J. Natl. Cancer Inst. 88, 1110-1117 (1996).
10. Y. TAKEBAYASHI, K. YAMADA, K. MIYADERA, T. SUMIZAWA, T. FURUKAWA, F. KINOSHITA, D. AOKI, H. OKUMURA, Y. YAMADA, S. AKIYAMA and T. AIKOU, The activity and expression of thymidine phosphorylase in human solid tumours, European J. Cancer 32A, 1227-1232 (1996).
11. T. S. O'BRIEN, S. B. FOX, A. J. DICKINSON, H. TURLEY, M. WESTWOOD, A. MOGHADDAM, K. C. GATTER, R. BICKNELL and A. L. HARRIS, Expression of the angiogenic factor thymidine phosphorylase/platelet-derived endothelial cell growth factor in primary bladder cancers, Cancer Research 56, 4799-4804 (1996).
12. S. B. FOX, M. WESTWOOD, A. MOGHADDAM, M. COMLEY, H. TURLEY, R. M. WHITEHOUSE, R. BICKNELL, K. C. GATTER and A. L. HARRIS, The angiogenic factor platelet-derived endothelial cell growth factor/thymidine phosphorylase is up-regulated in breast cancer epithelium and endothelium, British J. Cancer 73, 275-280 (1996).
13. L. GRIFFITHS, G. U. DACHS, R. BICKNELL, A. L. HARRIS and I. J. STRATFORD, The influence of oxygen tension and pH on the expression of platelet-derived endothelial cell growth factor/thymidine phosphorylase in human breast tumor cells grown in vitro and in vivo, Cancer Res. 57, 570-572 (1997).
14. H. YOSHIJI, S. R. HARRIS and U. P. THORGEIRSSON, Vascular endothelial growth factor is essential for initial but not continued in vivo growth of human breast carcinoma cells, Cancer Res. 57, 3924-3928 (1997).
15. H. ABEDI and I. ZACHARY, Vascular endothelial growth factor stimulates tyrosine phosphorylation and recruitment to new focal adhesions of focal adhesion kinase and paxillin in endothelial cells, J. Biol. Chem. 272, 15442-15451 (1997).
16. B. ANAND-APTE, L. BAO, R. SMITH, K. IWATA, B. R. OLSEN, B. ZETTER and S. S. APTE, A review of tissue inhibitor of metalloproteinases-3 (TIMP-3) and experimental analysis of its effect on primary tumor growth, Biochemistry and Cell Biology 74, 853-862 (1996).
17. D. FUKUMURA, F. YUAN, W. L. MONSKY, Y. CHEN and R. K. JAIN, Effect of host microenvironment on the microcirculation of human colon adenocarcinoma, Am. J. Pathology 151, 679-688 (1997).
18. J. R. LESS, M. C. POSNER, T. C. SKALAK, N. WOLMARK and R. K. JAIN, Geometric resistance and microvascular network architecture of human colorectal carcinoma, Microcirculation 4, 25-33 (1997).
19. R. K. JAIN and M. THE EUGENE, Landis Award Lecture 1996. Delivery of molecular and cellular medicine to solid tumors, Microcirculation 4, 1-23 (1997).
20. B. A. TEICHER, A systems approach to cancer therapy. (Antioncogenics + standard cytotoxics → mechanism(s) of interaction), Cancer and Metastasis Reviews 15, 247-272 (1996).
21. L. E. BENJAMIN and E. KESHET, Conditional switching of vascular endothelial growth factor (VEGF) expression in tumors: induction of endothelial cell shedding and regression of hemangioblastoma-like vessels by VEGF withdrawal, Proc. Natl. Acad. Sciences, U.S.A. 94, 8761-8766 (1997).
22. L. F. BROWN, M. DETMAR, K. CLAFFEY, J. A. NAGY, D. FENG, A. M. DVORAK and H. F. DVORAK, Vascular permeability factor/vascular endothelial growth factor: a multifunctional angiogenic cytokine, Exs 79, 233-269 (1997).
23. R. J. D'AMATO, M. S. LOUGHNAN, E. FLYNN and J. FOLKMAN, Thalidomide is an inhibitor of angiogenesis, Proc. Natl. Acad. Sciences, U.S.A. 91, 4082-4085 (1994).
24. M. TOI, K. INADA, H. SUZUKI and T. TOMINAGA, Tumor angiogenesis in breast cancer: its importance as a prognostic indicator and the association with vascular endothelial growth factor expression, Breast Cancer Research and Treatment 36, 193-204 (1995).
25. K. H. PLATE, G. BREIER and W. RISAU, Molecular mechanisms of developmental and tumor angiogenesis, Brain Pathology 4, 207-218 (1994).
26. M. TOI, K. INADA, S. HOSHINA, H. SUZUKI, S. KONDO and T. TOMINAGA, Vascular endothelial growth factor and platelet-derived endothelial cell growth factor are frequently coexpressed in highly vascularized human breast cancer, Clinical Cancer Res. 1, 961-964 (1995).
27. A. J. GUIDI, G. ABU-JAWDEH, B. BERSE, R. W. JACKMAN, K. TOGNAZZI, H. F. DVORAK and L. F. BROWN, Vascular permeability factor (vascular endothelial growth factor) expression and angiogenesis in cervical neoplasia, J. Natl. Cancer Inst. 87, 1237-1245 (1995).
28. J. MATTERN, R. KOOMAGI and M. VOLM, Vascular endothelial growth factor expression and angiogenesis in non-small cell lung carcinomas, Intl. Oncology 6, 1059-1062 (1995).
29. K. MAEDA, Y. S. CHUNG, Y. OGAWA, S. TAKATSUKA, S. M. KANG, M. OGAWA, T. SAWADA and M. SOWA, Prognostic value of vascular endothelial growth factor expression in gastric carcinoma, Cancer 77, 858-863 (1996).
30. Y. TAKAHASHI, Y. KITADAI, C. D. BUCANA, K. R. CLEARY and L. M. ELLIS, Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis and proliferation of human colon cancer, Cancer Res. 55, 3964-3968 (1995).
31. A. OBERMAIR, E. KUCERA, K. MAYERHOFER, P. SPEISER, M. SEIFERT, K. CZERWENKA, A. KAIDER, S. LEODOLTER, C. KAINZ and R. ZEILLINGER, Vascular endothelial growth factor (VEGF) in human breast cancer: correlation with disease-free survival, Intl. J. Cancer 74, 455-458 (1997).
32. L. F. BROWN, B. BERSE, R. W. JACKMAN, K. TOGNAZZI, A. J. GUIDI, H. F. DVORAK, D. R. SENGER, J. L. CONNOLLY and S. J. SCHNITT, Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in breast cancer, Human Pathology 26, 86-91 (1995).
33. C. A. BOOCOCK, D. S. CHARNOCK-JONES, A. M. SHARKEY, J. MCLAREN, P. J. BARKER, K. A. WRIGHT, P. R. TWENTYMAN and S. K. SMITH, Expression of vascular endothelial growth factor and its receptors fit and KDR in ovarian carcinoma, J. Natl. Cancer Inst. 87, 506-516 (1995).
34. K. H. PLATE, G. BREIER, B. MILLAUER, A. ULLRICH and W. RISAU, Up-regulation of vascular endothelial growth factor and its cognate receptors in a rat glioma model of tumor angiogenesis, Cancer Res. 53, 5822-5827 (1993).
35. L. F. BROWN, B. BERSE, R. W. JACKMAN, K. TOGNAZZI, E. J. MANSEAU, H. F. DVORAK and D. R. SENGER, Increased expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in kidney and bladder carcinomas, Am. J. Pathology 143, 1255-1262 (1993).
36. P. XIA, L. P. AIELLO, H. ISHII, Z. Y. JIANG, D. J. PARK, G. S. ROBINSON, H. TAKAGI, W. P. NEWSOME, M. R. JIROUSEK and G. L. KING, Characterization of vascular endothelial growth factor's effect on the activation of protein kinase C, its isoforms, and endothelial cell growth, J. Clinical Investigation 98, 2018-2026 (1996).
37. D. GUO, Q. JIA, H. Y. SONG, R. S. WARREN and D. B. DONNER, Vascular endothelial cell growth factor promotes tyrosine phosphorylation of mediators of signal transduction that contain SH2 domains. Association with endothelial cell proliferation, J. Biol. Chem. 270, 6729-6733 (1995).
38. A. SAWANO, T. TAKAHASHI, S. YAMAGUCHI and M. SHIBUYA, The phosphorylated 1169-tyrosine containing region of fit-1 kinase (VEGFR-1) is a major binding site for PLCgamma, Biochem. Biophys. Res. Commun. 238, 487-491 (1997).
39. M. MOHAMMADI, I. DIKIC, A. SOROKIN, W. H. BURGESS, M. JAYE and J. SCHLESSINGER, Identification of six novel autophosphorylation sites on fibroblast growth factor receptor 1 and elucidation of their importance in receptor activation and signal transduction, Molecular and Cellular Biology 16, 977-989 (1996).
40. Y. NISHIZUKA, Intracellular signaling by hydrolysis of phospholipids and activation of protein kinase C, Science 258, 607-614 (1992).
41. M. R. JIROUSEK, J. R. GILLIG, C. M. GONZALEZ, W. F. HEATH, J. H. MCDONALD, D. A. NEEL, C. J. RITO, U. SINGH, L. E. STRAMM, A. MELIKIAN-BADALIAN, M. BAEVSKY, L. M. BALLAS, S. E. HALL, L. L. WINNEROSKI and M. M. FAUL, (S)-13-[(dimethylamino)methyl]-10,11,14,15-tetrahydro-4,9:16, 21-dimetheno-1H, 13H-dibenzo[e,k]pyrrolo[3,4-h][1,4,13]oxadiazacyclohexadecene-1,3(2H)-d ione (LY333531) and related analogues: isozyme selective inhibitors of protein kinase C beta, J. Medicinal Chem. 39, 2664-2671 (1996).
42. R. P. DANIS, D. P. BINGAMAN, M. JIROUSEK and Y. YANG, Inhibition of intraocular neovascularization caused by retinal ischemia in pigs by PKCbeta inhibition with LY333531, Investigative Ophthalmology and Visual Science 39, 171-179 (1998).
43. L. P. AIELLO, S. E. BURSELL, A. CLERMONT, E. DUH, H. ISHII, C. TAKAGI, F. MORI, T. A. CIULLA, K. WAYS, M. JIROUSEK, L. E. SMITH and G. L. KING, Vascular endothelial growth factor-induced retinal permeability is mediated by protein kinase C in vivo and suppressed by an orally effective beta-isoform-selective inhibitor, Diabetes 46, 1473-1480 (1997).
44. H. ISHII, M. R. JIROUSEK, D. KOYA, C. TAKAGI, P. XIA, A. CLERMONT, S. E. BURSELL, T. S. KERN, L. M. BALLAS, W. F. HEATH, L. E. STRAMM, E. P. FEENER and G. L. KING, Amelioration of vascular dysfunctions in diabetic rats by an oral PKC beta inhibitor, Science 272, 728-731 (1996).
45. B. A. TEICHER, S. A. HOLDEN, G. ARA, E. ALVAREZ, Z. D. HUANG, Y. N. CHEN and H. BREM, Potentiation of cytotoxic cancer therapies by TNP-470 alone and with other anti-angiogenic agents, Intl. J. Cancer 57, 920-925 (1994).
46. Y. KAKEJI and B. A. TEICHER, Preclinical studies of the combination of angiogenic inhibitors with cytotoxic agents, Investigational New Drugs 15, 39-48 (1997).
47. J. FOGH, J. M. FOGH and T. ORFEO, One hundred and twenty-seven cultured human tumor cell lines producing tumors in nude mice, J. Natl. Cancer Inst. 59, 221-226 (1977).
48. B. TEICHER, A. ES and Z. HUANG, Antiangiogenic agents potentiate cytotoxic cancer therapies against primary and metastatic disease, Cancer Res. 52, 6702-6704 (1992).
49. B. TEICHER, S. HOLDEN, G. ARA, E. ALVAREZ, Z. HUANG, Y. CHEN and V. KHANDEKAR, Beta-cyclodextrin tetradecasulfate/tetrahydrocortisol ± minocycline as modulators of cancer therapies in vitro and in vivo against primary and metastatic Lewis lung carcinoma, Cancer Chemotherapy and Pharmacology 33, 229-238 (1993).
50. B. A. TEICHER, S. A. HOLDEN, G. ARA, T. KORBUT and K. MENON, Comparison of several antiangiogenic regimens alone and with cytotoxic therapies in the Lewis lung carcinoma, Cancer Chemotherapy and Pharmacology 38, 169-177 (1996).
51. B. A. TEICHER, S. A. HOLDEN, G. ARA, N. P. DUPUIS, F. LIU, J. YUAN, M. IKEBE and Y. KAKEJI, Influence of an anti-angiogenic treatment on 9L gliosarcoma: oxygenation and response to cytotoxic therapy, Intl. J. Cancer 61, 732-737 (1995).
52. T. W. GRUNT, A. LAMETSCHWANDTNER and K. KARRER, The characteristic structural features of the blood vessels of the Lewis lung carcinoma (a light microscopic and scanning electron microscopic study). Scanning Electron Microscopy 575-589 (1986).
53. T. W. GRUNT, A. LAMETSCHWANDTNER, K. KARRER and O. STAINDL, The angioarchitecture of the Lewis lung carcinoma in laboratory mice (a light microscopic and scanning electron microscopic study). Scanning Electron Microscopy 557-573 (1986).
54. E. RUBIN, S. KHARBANDA, H. GUNJI, R. WEICHSELBAUM and D. KUFE, cis-Diamminedichloroplatinum(II) induces c-jun expression in human myeloid leukemia cells: potential involvement of a protein kinase C-dependent signaling pathway, Cancer Res. 52, 878-882 (1992).
55. S. KHARBANDA, R. DATTA and D. KUFE, Regulation of c-jun gene expression in HL-60 leukemia cells by 1-beta-D-arabinofuranosylcytosine. Potential involvement of a protein kinase C dependent mechanism, Biochemistry 30, 7947-7952 (1991).
56. A. HAIMOVITZ-FRIEDMAN, C. C. KAN, D. EHLEITER, R. S. PERSAUD, M. MCLOUGHLIN, Z. FUKS and R. N. KOLESNICK, Ionizing radiation acts on cellular membranes to generate ceramide and initiate apoptosis, J. Exptl. Medicine 180, 525-535 (1994).
57. D. E. HALLAHAN, S. VIRUDACHALAM, M. L. SHERMAN, E. HUBERMAN, D. W. KUFE and R. R. WEICHSELBAUM, Tumor necrosis factor gene expression is mediated by protein kinase C following activation by ionizing radiation, Cancer Res. 51, 4565-4569 (1991).
58. N. M. HASAN, P. J. PARKER and G. E. ADAMS, Induction and phosphorylation of protein kinase C-alpha and mitogen-activated protein kinase by hypoxia and by radiation in Chinese hamster V79 cells, Radiation Res. 145, 128-133 (1996).
59. N. ISAKOV, D. GALRON, T. MUSTELIN, G. R. PETTIT and A. ALTMAN, Inhibition of phorbol ester-induced T cell proliferation by bryostatin is associated with rapid degradation of protein kinase C, J. Immunology 150, 1195-1204 (1993).
60. Z. SZALLASI, M. F. DENNING, C. B. SMITH, A. A. DLUGOSZ, S. H. YUSPA, G. R. PETTIT and P. M. BLUMBERG, Bryostatin 1 protects protein kinase C-delta from down-regulation in mouse keratinocytes in parallel with its inhibition of phorbol ester-induced differentiation, Molecular Pharmacology 46, 840-850 (1994).
61. Z. SZALLASI, C. B. SMITH, G. R. PETTIT and P. M. BLUMBERG, Differential regulation of protein kinase C isozymes by bryostatin 1 and phorbol 12-myristate 13-acetate in NIH 3T3 fibroblasts, J. Biol. Chem. 269, 2118-2124 (1994).
62. S. GRANT, W. D. JARVIS, P. S. SWERDLOW, A. J. TURNER, R. S. TRAYLOR, H. J. WALLACE, P. S. LIN, G. R. PETTIT and D. A. GEWIRTZ, Potentiation of the activity of 1-beta-D-arabinofuranosylcytosine by the protein kinase C activator bryostatin 1 in HL-60 cells: association with enhanced fragmentation of mature DNA, Cancer Res. 52, 6270-6278 (1992).
63. W. D. JARVIS, L. F. POVIRK, A. J. TURNER, R. S. TRAYLOR, D. A. GEWIRTZ, G. R. PETTIT and S. GRANT, Effects of bryostatin 1 and other pharmacological activators of protein kinase C on 1-[beta-D-arabinofuranosyl]cytosine-induced apoptosis in HL-60 human promyelocytic leukemia cells, Biochem. Pharmacol. 47, 839-852 (1994).
64. D. J. MCCONKEY, P. HARTZELL, M. JONDAL and S. ORRENIUS, Inhibition of DNA fragmentation in thymocytes and isolated thymocyte nuclei by agents that stimulate protein kinase C, J. Biol. Chem. 264, 13399-13402 (1989).
65. L. D. TOMEI, P. KANTER and C. E. WENNER, Inhibition of radiation-induced apoptosis in vitro by tumor promoters, Biochem. Biophys. Res. Commun. 155, 324-331 (1988).
66. M. FRIEDLANDER, P. C. BROOKS, R. W. SHAFFER, C. M. KINCAID, J. A. VARNER and D. A. CHERESH, Definition of two angiogenic pathways by distinct alpha v integrins, Science 270, 1500-1502 (1995).